GT Biopharma Q4 EPS $(2.14) Beats $(2.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
GT Biopharma (NASDAQ:GTBP) reported a Q4 EPS loss of $(2.14), surpassing the analyst consensus estimate of $(2.70) by 20.74%. This represents a 60.37% improvement over the $(5.40) per share loss from the same period last year.
March 26, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GT Biopharma reported a smaller than expected Q4 loss, beating estimates and showing significant year-over-year improvement.
Beating the EPS estimate by a significant margin and showing a substantial year-over-year improvement in losses indicates operational efficiency and potential for future growth. This positive earnings report is likely to instill investor confidence and could lead to a short-term uptick in GTBP's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100